Literature DB >> 21991018

The Treatment of Lyell'S Syndrome: our Experience.

B Napoli1, N D'Arpa, M Masellis.   

Abstract

In view of the pathogenic mechanisms of Lyell's syndrome, we consider support-only treatment to be insufficient and believe it is necessary to administer i.v. human immunoglobulin. Because of the potentially severe side effects of the high doses usually recommended, we prefer to use low doses (no more than 5 g per day) in association with the administration of fresh frozen plasma, which offers the benefits of the high protein content in the albumin (with its resuscitatory function) and its globulin content (functioning as a specific therapy for Lyell's syndrome). We present the latest cases we have observed and treated using this protocol.

Entities:  

Keywords:  experience; lyell’s; syndrome; treatment

Year:  2006        PMID: 21991018      PMCID: PMC3188016     

Source DB:  PubMed          Journal:  Ann Burns Fire Disasters        ISSN: 1592-9558


  18 in total

1.  Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins.

Authors:  G G Tóth; M F Jonkman
Journal:  Br J Dermatol       Date:  1999-09       Impact factor: 9.302

Review 2.  [Indications for intra-venous immunoglobulin treatment in rheumatic diseases].

Authors:  F Laghi Pansini; P L Capecchi; F Bellisai; P E Lazzerini; M Galeazzi
Journal:  Reumatismo       Date:  2003 Oct-Dec

Review 3.  Toxic epidermal necrolysis (Lyell syndrome).

Authors:  J C Roujeau; O Chosidow; P Saiag; J C Guillaume
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

4.  Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus.

Authors:  P Saiag; E Caumes; O Chosidow; J Revuz; J C Roujeau
Journal:  J Am Acad Dermatol       Date:  1992-04       Impact factor: 11.527

5.  Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita.

Authors:  H Kofler; B Wambacher-Gasser; G Topar; G Weinlich; G Schuler; H Hintner; N Romani; P Fritsch
Journal:  J Am Acad Dermatol       Date:  1997-02       Impact factor: 11.527

6.  Ileal involvement in toxic epidermal necrolysis (Lyell syndrome).

Authors:  P Michel; P Joly; P Ducrotte; J Hemet; I Leblanc; P Lauret; E Lerebours; R Colin
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

7.  Disseminated intravascular coagulation associated with toxic epidermal necrolysis (Lyell's syndrome).

Authors:  J Kvasnicka; J Rezác; J Svejda; H Duchková; F Kaze; P Zalud; J Richter
Journal:  Br J Dermatol       Date:  1979-05       Impact factor: 9.302

8.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Authors:  I Viard; P Wehrli; R Bullani; P Schneider; N Holler; D Salomon; T Hunziker; J H Saurat; J Tschopp; L E French
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

9.  Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children.

Authors:  Payam Tristani-Firouzi; Marta J Petersen; Jeffrey R Saffle; Stephen E Morris; John J Zone
Journal:  J Am Acad Dermatol       Date:  2002-10       Impact factor: 11.527

10.  Acute and chronic respiratory complications of toxic epidermal necrolysis.

Authors:  R A McIvor; J Zaidi; W J Peters; R H Hyland
Journal:  J Burn Care Rehabil       Date:  1996 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.